| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
40,450,000 |
| Market
Cap: |
1.74(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$18.65 - $44.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with unmet medical need. Co.'s portfolio of assets include: ARCALYST® (rilonacept) is for the treatment of Cryopyrin-Associated Periodic Syndrome; mavrilimumab is targeting granulocyte-macrophage colony stimulating factor receptor alpha; vixarelimab is evaluating vixarelimab for the potential treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404 is a humanized monoclonal antibody that is designed to inhibit the CD40-CD154 interaction.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
135,548 |
919,660 |
1,727,281 |
2,414,330 |
| Total Sell Value |
$5,675,566 |
$34,361,870 |
$57,269,516 |
$73,661,830 |
| Total People Sold |
3 |
8 |
8 |
8 |
| Total Sell Transactions |
10 |
28 |
68 |
95 |
| End Date |
2025-11-09 |
2025-08-08 |
2025-02-07 |
2024-02-08 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Quart Barry D |
|
– • – |
2026-02-04 |
4 |
AS |
$45.02 |
$117,142 |
D/D |
(2,602) |
12,546 |
|
- |
|
| Quart Barry D |
|
– • – |
2026-02-04 |
4 |
OE |
$15.47 |
$40,253 |
D/D |
2,602 |
15,148 |
|
- |
|
| Quart Barry D |
|
– • – |
2026-02-03 |
4 |
AS |
$45.27 |
$567,143 |
D/D |
(12,528) |
12,546 |
|
- |
|
| Quart Barry D |
|
– • – |
2026-02-03 |
4 |
OE |
$15.47 |
$193,808 |
D/D |
12,528 |
25,074 |
|
- |
|
| Quart Barry D |
|
– • – |
2026-02-02 |
4 |
AS |
$45.00 |
$37,350 |
D/D |
(830) |
12,546 |
|
- |
|
| Quart Barry D |
|
– • – |
2026-02-02 |
4 |
OE |
$15.47 |
$12,840 |
D/D |
830 |
13,376 |
|
- |
|
| Levy Richard S |
|
– • – |
2026-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
683 |
19,157 |
|
- |
|
| Ragosa Mark |
CHIEF FINANCIAL OFFICER |
• – – |
2026-01-08 |
4 |
AS |
$41.89 |
$502,680 |
D/D |
(12,000) |
19,086 |
|
5% |
|
| Quart Barry D |
|
– • – |
2025-12-15 |
4 |
AS |
$41.51 |
$835,555 |
D/D |
(20,129) |
12,546 |
|
6% |
|
| Quart Barry D |
|
– • – |
2025-12-15 |
4 |
OE |
$10.36 |
$208,536 |
D/D |
20,129 |
32,675 |
|
- |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-12-15 |
4 |
AS |
$41.56 |
$500,715 |
D/D |
(12,048) |
16,666 |
|
6% |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-12-15 |
4 |
OE |
$8.83 |
$52,980 |
D/D |
6,000 |
28,714 |
|
- |
|
| Ragosa Mark |
CHIEF FINANCIAL OFFICER |
• – – |
2025-12-08 |
4 |
AS |
$41.49 |
$1,777,473 |
D/D |
(42,841) |
31,086 |
|
6% |
|
| Ragosa Mark |
CHIEF FINANCIAL OFFICER |
• – – |
2025-12-08 |
4 |
OE |
$10.76 |
$486,025 |
D/D |
42,841 |
73,927 |
|
- |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-11-26 |
4 |
AS |
$42.89 |
$8,578 |
D/D |
(200) |
22,714 |
|
3% |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-11-26 |
4 |
OE |
$22.89 |
$4,578 |
D/D |
200 |
22,914 |
|
- |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-11-17 |
4 |
AS |
$40.08 |
$514,224 |
D/D |
(12,470) |
22,714 |
|
6% |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-11-17 |
4 |
OE |
$8.83 |
$57,395 |
D/D |
6,500 |
35,184 |
|
- |
|
| Patel Sanj K |
CHAIRMAN & CEO |
• • – |
2025-11-13 |
4 |
GA |
$0.00 |
$0 |
I/I |
60,000 |
60,000 |
|
- |
|
| Patel Sanj K |
CHAIRMAN & CEO |
• • – |
2025-11-13 |
4 |
GD |
$0.00 |
$0 |
I/I |
60,000 |
51,794 |
|
- |
|
| Ragosa Mark |
CHIEF FINANCIAL OFFICER |
• – – |
2025-11-12 |
4 |
AS |
$40.94 |
$814,706 |
D/D |
(19,900) |
31,086 |
|
8% |
|
| Ragosa Mark |
CHIEF FINANCIAL OFFICER |
• – – |
2025-11-12 |
4 |
OE |
$30.93 |
$615,507 |
D/D |
19,900 |
50,986 |
|
- |
|
| Patel Sanj K |
CHAIRMAN & CEO |
• • – |
2025-11-12 |
4 |
GA |
$0.00 |
$0 |
I/I |
111,794 |
111,794 |
|
- |
|
| Patel Sanj K |
CHAIRMAN & CEO |
• • – |
2025-11-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
111,794 |
0 |
|
- |
|
| Paolini John F. |
CHIEF MEDICAL OFFICER |
• – – |
2025-10-31 |
4 |
AS |
$37.14 |
$3,065,610 |
D/D |
(82,542) |
61,324 |
|
19% |
|
532 Records found
|
|
Page 1 of 22 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.51 (1.2%) 
